VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog🤝Partner
Illustration for: Jersey Mike's Raises $1B in Blackstone-Backed NYSE Debut
Value Add VC/Pulse/IPO$1B IPO

Jersey Mike's Raises $1B in Blackstone-Backed NYSE Debut

Jersey Mike's began trading on the NYSE under ticker JMKE after pricing its IPO at $23 a share, raising roughly $1 billion and valuing the sandwich chain at $7.3 billion, though shares opened below the IPO price as Blackstone retains majority voting control.

By the Numbers

$23/share
IPO price
~$1B
Raised
$7.3B
Valuation
~-2%
Day-1 move
TC
Trace Cohen
Early-stage VC & angel · Founder, New York Venture Partners
July 30, 2026
2 min read
ShareXLinkedInEmail

THE RUNDOWN

1

Jersey Mike's priced its IPO at $23 per share, the top of its range, selling 43.5 million Class A shares to raise approximately $1 billion and value the company at $7.3 billion, before opening at $21 and trading down roughly 2% on its first day

2

Blackstone, which acquired majority control of Jersey Mike's for roughly $8 billion including debt, will retain control of approximately two-thirds of the company's shareholder votes after the IPO through a dual-class share structure

3

The offering included a 30-day underwriter option to purchase up to 6.5 million additional shares to cover over-allotments, a standard IPO mechanism that can modestly increase total proceeds if exercised

4

The debut lands alongside Reformation's flat NYSE opening the same week, giving investors two consumer-brand IPOs to compare in a market that has shown considerably more enthusiasm for AI-adjacent and biotech listings than consumer names this earnings season

TC

The VC Read · Trace's Take

Trace Cohen

A dual-class structure that hands public investors two-thirds less voting power than their capital contribution is exactly the kind of detail that gets buried in the excitement of a $1 billion raise and then resurfaces as a governance fight three years later. The flat-to-down reception for both Jersey Mike's and Reformation this week versus Apnimed's 37% pop is the market drawing a clean line: growth and differentiation get rewarded, mature consumer brands with sponsor control don't, no matter how recognizable the name.

Tech IPO Tracker →

Analysis

Jersey Mike's began trading on the New York Stock Exchange under ticker JMKE on Thursday after pricing its IPO at $23 per share, the top of its marketed range, raising approximately $1 billion and valuing the sandwich chain at $7.3 billion. Shares nonetheless opened below the IPO price at $21 and traded down roughly 2% through the session, a soft debut for one of the year's more closely watched consumer listings.

The offering comprised 43.5 million shares of Class A common stock, with underwriters holding a 30-day option to purchase up to an additional 6.5 million shares to cover over-allotments if demand warrants. Blackstone, which had acquired majority control of Jersey Mike's for roughly $8 billion including debt in a prior transaction, retains control of approximately two-thirds of the company's shareholder votes through a dual-class structure -- meaning public investors are buying meaningful economic exposure without commensurate governance influence.

The soft opening fits a broader pattern this week: Reformation, the Permira-backed womenswear retailer, also opened flat in its own NYSE debut the same day, giving the market two consumer-brand IPOs to compare directly. Both landed considerably cooler than Apnimed's 37% pop in its Nasdaq debut a day later, reinforcing that 2026's IPO window is rewarding biotech and differentiated growth stories more generously than mature consumer brands, however strong their underlying unit economics.

Jersey Mike's brings real scale to the public markets -- a nationally recognized sandwich chain with an established franchise model -- but investors appear to be pricing in the same private-equity-exit dynamic that has weighed on other sponsor-backed consumer IPOs this year: strong brand recognition doesn't automatically translate into the growth multiple public markets reward, particularly when a financial sponsor retains outsized voting control post-listing.

For franchise and consumer-brand investors, the debut is a useful data point on where the market's appetite currently sits: real, profitable, well-known consumer businesses are getting priced for what they are rather than commanding growth-stock multiples, a discipline that has been notably absent in AI-adjacent listings this year. What to watch: whether Jersey Mike's stock stabilizes above its IPO price in coming weeks, and whether Blackstone's retained control becomes a point of tension with public shareholders over capital allocation decisions.

ShareXLinkedInEmail

More on

Blackstone →Jersey Mike's →

Reported by CNBC · Analysis by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.

Read Next

IPO· Aug 9, 2026

What BofA's Extreme Bull Signal Means for Your Marks

Illustration for: What BofA's Extreme Bull Signal Means for Your Marks
IPO

What BofA's Extreme Bull Signal Means for Your Marks

BofA's Bull & Bear indicator hit 9.7, its highest since 2021 and above the firm's own 8.0 sell threshold — a trace's-take on what that extreme reading should change about how GPs mark portfolio companies against public comps.

IPO· Aug 8, 2026

Biotech IPOs Are Pricing Above Range Again

Illustration for: Biotech IPOs Are Pricing Above Range Again
IPO$532.5M combined

Biotech IPOs Are Pricing Above Range Again

BlossomHill and Braveheart Bio both upsized and priced above their original ranges this week, the clearest two-deal signal yet that the biotech IPO window -- closed to all but the strongest names in 2024-2025 -- is reopening.

IPO· Aug 7, 2026

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

Illustration for: BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq
IPO$150M IPO

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

BlossomHill Therapeutics priced an upsized IPO at $16 a share for $150M and began trading on Nasdaq under BLSM, more than 50% above the $100M target Pulse flagged when the company first filed.

@Trace_Cohen·t@nyvp.com